Zenas Biopharma Inc (ZBIO)
Business numbers score is below the middle.
ZBIO scores higher than 55% of the 1,101 tickers we compare it with (Health Care).
As of 9 October 2026, Zenas Biopharma Inc (ZBIO) scores 43 out of 100 on the Market Census six-factor composite, which puts it at the Average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 9 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 0.64× 30-day average
- 52-week range
- 13.50 – 44.60
- Market cap
- $2.04B
- Earnings date
- 10 Nov 2026
- Volume
- 429,816
- Avg. volume (30d)
- 672,671
- Open
- 26.18
- Previous close
- 26.24
- Day's range (regular session)
- 26.18 – 27.64
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- 0.70
- P/E (TTM)
- —
- EPS (TTM)
- -8.97
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
What the score says about ZBIO right now
Zenas Biopharma Inc (ZBIO) currently scores 43/100 on the Market Census six-factor composite, at the Average score level. ZBIO is +3.89% on the day and -3.30% over five sessions as of the most recent tick. Average sits in the middle. The good and the bad in ZBIO's data roughly balance out right now. ZBIO's strongest factor is price trend at 55/100 — a fairly good read on which way the price has been going. The weakest factor is company finances at 0/100 — well below average company numbers. A low company-finances reading is the canonical "value trap" warning: technical setups on broken fundamentals don't tend to compound.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See ZBIO in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent ZBIO news
Latest headlines that name Zenas Biopharma, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).
- Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026Yahoo
- Zenas BioPharma to Host Virtual R&D EventYahoo
- Zenas BioPharma: Obexelimab Is Being Graded On The Wrong CurveSeekingAlpha
- Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease TranscriptSeekingAlpha
- Can Zenas BioPharma’s (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn?Yahoo
We hide 3 more that told readers to buy or sell, or gave a price target.
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Health Care right now
Six health care tickers whose composite scores are closest to ZBIO’s 43, all within 1 point.
Sorted by closeness to ZBIO’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.